Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cingulate Inc (CING)

Cingulate Inc (CING)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,359
  • Shares Outstanding, K 5,010
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,530 K
  • 60-Month Beta -0.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CING with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -24.40
  • Most Recent Earnings $-6.00 on 11/13/23
  • Latest Earnings Date 05/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -2.20
  • Number of Estimates 1
  • High Estimate -2.20
  • Low Estimate -2.20
  • Prior Year -7.00
  • Growth Rate Est. (year over year) +68.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7500 +12.00%
on 04/15/24
1.1700 -28.21%
on 04/01/24
-0.2700 (-24.32%)
since 03/25/24
3-Month
0.7500 +12.00%
on 04/15/24
4.8600 -82.72%
on 02/01/24
-3.1000 (-78.68%)
since 01/25/24
52-Week
0.7500 +12.00%
on 04/15/24
23.7980 -96.47%
on 04/26/23
-20.8600 (-96.13%)
since 04/25/23

Most Recent Stories

More News
Cingulate Inc. To Present at the LD Micro Main Event XVI

Presentation on Wednesday, October 4th at 02:30 PM PTKansas City, Kansas--(Newsfile Corp. - September 21, 2023) - Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision...

CING : 0.8400 (-3.45%)
Stocks Set to Open Lower as Bank Shares Fall

March S&P 500 futures ( ESH23 ) are down -1.2%, and March Nasdaq 100 E-Mini futures ( NQH23 ) are down -0.91% this morning as investors weighed the emergency measures presented by the U.S. financial authorities...

ESH23 : 3,957.05s (-0.09%)
NQM24 : 17,751.00 (+1.04%)
NKLA : 0.6000 (-3.23%)
MRK : 130.72 (+2.93%)
TFC : 37.97 (-2.11%)
CING : 0.8400 (-3.45%)
BTI : 29.40 (-0.31%)
FRC : 3.51 (-43.30%)
WAL : 58.63 (-1.25%)
Cingulate Inc. Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

$5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc....

CINGW : 0.0150 (+29.31%)
CING : 0.8400 (-3.45%)
Kansas City Business Journal Names Cingulate’s Louis G. Van Horn a 2022 Chief Financial Officer of the Year

KC Business Veteran, Two-Time Award Winner, Helped Lead Cingulate to 2021 IPO...

CINGW : 0.0150 (+29.31%)
CING : 0.8400 (-3.45%)
Cingulate Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

CTx-2103 (buspirone) is the Third Candidate Using Cingulate’s Proprietary Precision Timed Release™ Drug Delivery Platform Technology for Once-daily Dosing...

CINGW : 0.0150 (+29.31%)
CING : 0.8400 (-3.45%)
Cingulate to Present at Diamond Equity Research 2022 Virtual Emerging Growth Invitational

KANSAS CITY, Kan., June 17, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary...

CINGW : 0.0150 (+29.31%)
CING : 0.8400 (-3.45%)
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

KANSAS CITY, Kan., June 02, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary...

CINGW : 0.0150 (+29.31%)
CING : 0.8400 (-3.45%)
Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders

Active Pharmaceutical Ingredient – Buspirone – One of the Most Widely Prescribed Agents in $5.5B U.S. Anxiety Market, Which Must be Taken Multiple Times...

CINGW : 0.0150 (+29.31%)
CING : 0.8400 (-3.45%)
Cingulate to Present at H.C. Wainwright Global Investment Conference

KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary...

CINGW : 0.0150 (+29.31%)
CING : 0.8400 (-3.45%)
Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update

Announcement of First Dosage for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Releaseâ„¢ Platform (PTRâ„¢) ...

CINGW : 0.0150 (+29.31%)
CING : 0.8400 (-3.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release(TM) drug delivery platform technology to build and advance a pipeline of pharmaceutical products. Cingulate Inc. is based in KANSAS CITY, Kan.

See More

Key Turning Points

3rd Resistance Point 0.9568
2nd Resistance Point 0.9284
1st Resistance Point 0.8842
Last Price 0.8400
1st Support Level 0.8116
2nd Support Level 0.7832
3rd Support Level 0.7390

See More

52-Week High 23.7980
Fibonacci 61.8% 14.9937
Fibonacci 50% 12.2740
Fibonacci 38.2% 9.5543
Last Price 0.8400
52-Week Low 0.7500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar